ArticleHematology. American Society of Hematology. Education Program2021
What else do I need to worry about when treating graft-versus-host disease?
Article in Hematology. American Society of Hematology. Education Program, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 15 citations in OpenAlex.
- "They knew the same struggles": perceptions of a group coping skills intervention in patients with chronic graft-versus-host disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Trial
- Investigating the impact of chronic graft‑versus‑host disease on patient health‑related quality of life: perspectives from patients and carers.Health and quality of life outcomes · 2026Article
- A Pilot Clinical Trial of a Group Coping Intervention for English and Spanish Speakers with Chronic Graft-Versus-Host Disease.International journal of behavioral medicine · 2026Article
- A Pilot Clinical Trial of a Group Coping Intervention for English and Spanish Speakers with Chronic Graft-Versus-Host Disease.Research square · 2026Article
- Allogeneic Stem Cell Transplant in Hematological Disorders: A Decade of Experience.International journal of hematology-oncology and stem cell research · 2024Article
- A Biobehavioral Perspective on Caring for Allogeneic Hematopoietic Stem Cell Transplant Survivors with Graft-Versus-Host Disease.Transplantation and cellular therapy · 2024Article
- Multidisciplinary Management of Morbidities Associated with Chronic Graft-Versus-Host Disease.Clinical hematology international · 2024Review
- Chronic graft-versus-host disease. Part I: Epidemiology, pathogenesis, and clinical manifestations.Journal of the American Academy of Dermatology · 2024Review
- Understanding and treatment of cutaneous graft-versus-host-disease.Bone marrow transplantation · 2023Review
- Understanding the Needs and Lived Experiences of Patients With Graft-Versus-Host Disease: Real-World European Public Social Media Listening Study.JMIR cancer · 2023Article
- Inflammatory cytokines and depression symptoms following hematopoietic cell transplantation.Brain, behavior, and immunity · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) is the main cause of morbidity and mortality in allogeneic hematopoietic stem cell transplant survivors. Patients with acute and chronic GVHD often endure substantial symptom burden and quality of life (QOL) and functional impairments. Living with GVHD affects multiple domains of patient-reported QOL, physical functioning, and psychological well-being. Patients describe living with GVHD as a life-altering "full-time job" requiring unique knowledge, personal growth, and resilient coping strategies. Managing the supportive care needs of patients living with GVHD must include (1) monitoring of patient-reported QOL and symptom burden; (2) routine screening for psychological distress and implementing therapeutic strategies to treat depression, anxiety, and posttraumatic stress symptoms; (3) a systematic review of care needs by a multidisciplinary team experienced in managing transplant-related complications and organ-specific GVHD symptoms; and (4) ensuring optimal prevention and management of infection complications in this highly immunocompromised population. Improving the QOL in patients with GVHD requires a multidisciplinary approach with emphasis on aggressive symptom management, psychological coping, and promoting physical activity and rehabilitation in this population living with immense prognostic uncertainty and struggling to adapt to this difficult and unpredictable illness.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.